In this regard, the luminal A subtype is the most indolent BC and has the best prognosis; the TNBC type has a poor prognosis and is often associated with genetic mutations (BRCA 1) and HER2 positive subtypes benefit from targeted anti-HER2 therapy. Here, ERBB2 is linked to breast cancer.